Impact of Aversive Warnings on E-Cigarette Cessation
Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · May 26, 2023
Trial Information
Current as of July 05, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of strong visual health warnings to help young adults quit using e-cigarettes. E-cigarette use has been increasing among this age group, which raises health concerns. The researchers want to see if these warnings can make users more aware of the health risks and encourage them to stop using e-cigarettes. They will create warnings based on scientific research and test them with participants aged 18 to 29 who use e-cigarettes at least once a week. Some participants will see the health warnings, while others will not, allowing the researchers to compare the results.
If you're between 18 and 29 years old, understand basic English, and currently use e-cigarettes regularly, you might be eligible to join this study. Participants will complete online surveys, sharing their experiences and responses to the warnings. The researchers will follow up with participants three months later to see if the warnings helped them quit. This study aims to provide valuable insights into how visual warnings might be used to reduce e-cigarette use and improve public health.
Gender
ALL
Eligibility criteria
- • Age 18-29 years
- • Basic understanding of English
- • Not institutionalized
- • Currently use e-cigarettes at least once per week
About University Of California, San Diego
The University of California, San Diego (UCSD) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust focus on translational medicine, UCSD leverages its interdisciplinary approach to explore groundbreaking therapies and interventions across a wide range of medical fields. The university's state-of-the-art facilities and collaboration with top-tier faculty and researchers ensure a comprehensive and ethical framework for conducting clinical trials, ultimately aiming to enhance patient outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported